19 Jun 2025 • Analyzing 386,651 individuals has revealed that metabolic-associated fatty liver disease (MAFLD) markedly increases the risk of cardiometabolic multimorbidity (CMM).

Key Findings:

• Over 13.85 years, MAFLD more than doubled the risk of developing CMM in those without baseline disease (HR: 2.78).
• Among patients with a single condition, MAFLD raised the risk of progression to CMM by 21% in T2D (HR: 1.21), 90% in CHD (HR: 1.90), and 65% in stroke (HR: 1.65).

Multistate models confirmed MAFLD’s strong impact across disease transitions, highlighting its role as a key driver of multimorbidity.

Source: Frontiers | Read Full Story